Canna-Pet(TM) Launches Survey Investigating CBD Use in Animals
Company to Aid Scientific Inquiry With First Ever Public Survey of Its Kind
(firmenpresse) - BOULDER, CO -- (Marketwired) -- 02/03/15 -- the leading American innovator of over-the-counter cannabinoid products for animals marketed by Peak Pharmaceuticals, Inc. (OTCQB: CTCO) is looking for volunteer participants to complete what may be the very first comprehensive nationwide survey investigating the use of CBD-based products for animals.
The survey can be found at .
Company CEO Dr. Soren Mogelsvang states, "To the best of our knowledge, this survey represents the first research into product choice, frequency of use, target indications and outcomes for commercial hemp and cannabinoid based product use in animals." He continues, "With research extremely limited for the past 75 years, due to its legal status, the safety and efficacy of cannabis-based products remain controversial, and it is critically important for us to build a scientific foundation to demonstrate safety and efficacy of cannabinoid products. The survey will contribute an important component of our ongoing efforts to elevate our understanding of cannabinoid use in animals and may support development of second generation products."
Participants are advised the survey may take 5 to 10 minutes to complete and is completely anonymous. Because of the anonymity we can''t offer a thank you gift, other than the knowledge that your participation is greatly appreciated and we believe it will further the advancement of research into the amazing properties of hemp based cannabinoids including CBD. Please note that the survey ends February 28th.
Canna-Pet™ is the culmination of years of research and development to provide the benefits of CBD and hemp without the "high" typically associated with THC. Today, Canna-Pet™ offers over-the-counter CBD products for cats, dogs and other domesticated animals. The company uses non-GMO hemp as starting material and all products are proudly made in the USA. In addition to CBD, Canna-Pet products contain proprietary ratios of other cannabinoids and terpenes. Canna-Pet™ is the leading producer of safe, hemp-based, cannabinoid (CBD) containing products, which are available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: CTCO). Order online at: and join us on and .
For veterinary inquiries visit: .
FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.
Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company''s continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at . We seek Safe Harbor. For more information please visit .
:
Canna-Pet™ Support
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.02.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 1334501
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BOULDER, CO
Phone:
Kategorie:
Livestock
Anmerkungen:
Diese Pressemitteilung wurde bisher 366 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Canna-Pet(TM) Launches Survey Investigating CBD Use in Animals
"
steht unter der journalistisch-redaktionellen Verantwortung von
Canna-Pet (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
